SCHEMBL934587

SCHEMBL934587

c1ccc(CCC(C2CCCCC2)C2CCCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.49
ALDH1A1 P00352 1/20 0.49
TAAR1 Q96RJ0 1/20 0.46
EPHX2 P34913 5/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
EPHX1 P07099 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
ALOX12 P18054 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
SLC18A2 Q05940 1/20 0.43
GRIN2B Q13224 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16191445 0.85 HTT (0.54) HTTALDH1A1TAAR1EPHX2NPC1
SCHEMBL8040937 0.81 MEN1 (0.39) HTTALDH1A1EPHX2EPHX1KMT2A
SCHEMBL8040010 0.81 ALDH1A1 (0.42) ALDH1A1TAAR1NPC1RAB9AEPHX1
SCHEMBL8042890 0.81 HRH3 (0.45) HTTALDH1A1TAAR1NPC1RAB9A
SCHEMBL4564333 0.81 HTT (0.50) HTTALDH1A1TAAR1EPHX2NPC1
SCHEMBL8464214 0.81 EPHX1 (0.47) ALDH1A1TAAR1NPC1RAB9AEPHX1
SCHEMBL7209770 0.81 HTT (0.47) HTTALDH1A1TAAR1EPHX2NPC1
SCHEMBL28898677 0.81 EPHX1 (0.36) HTTALDH1A1EPHX2EPHX1
SCHEMBL3966885 0.80 EPHX2 (0.44) TAAR1EPHX2EPHX1TSHR
SCHEMBL9390743 0.79 ALDH1A1 (0.44) HTTALDH1A1TAAR1EPHX2SLC18A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238740-A1 NON-POLAR AND POLAR LEAVING GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-09-20 US disclosed
EP-2454216-A1 NON-POLAR AND POLAR LEAVING GROUPS Bayer Pharma Aktiengesellschaft (DE) 2012-05-23 EP disclosed
WO-2011006610-A1 NON-POLAR AND POLAR LEAVING GROUPS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238740-A1 NON-POLAR AND POLAR LEAVING GROUPS PGLS, RABGGTB, LNPEP HTT 3991/4885ALDH1A1 2845/4885TAAR1 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.